Literature DB >> 30304617

Using Post-Discharge Telephone Follow-Up by Nephrology Nurses to Reduce 30-Day Readmissions and Post-Discharge Complications for Adult Patients on Hemodialysis.

Gordon T Briscoe1, Amy Heerschap2,3, Catherine F Kane4, Beth D Quatrara5.   

Abstract

Hospital readmissions are responsible for considerable health care costs. About 35% of patients with end stage renal disease (ESRD) who are hospitalized are readmitted within 30 days of discharge (United States Renal Data System, 2017). Studies point to the considerable percentage of readmissions that are preventable through effective discharge planning and patient follow-up after discharge (Mistiaen & Poot, 2006). Telephone follow up is a high-quality, low-cost method of providing discharge follow up. This project examined the effectiveness of an evidence-based quality improvement process in providing post-discharge telephone follow up to adult patients on hemodialysis by experienced nephrology nurses through standardized unit workflow and leveraging of the electronic medical record (EMR). Results indicated a lower percentage of admissions from the emergency department (59.9% pre- vs. 55.4% post-intervention) and a lower percentage of 30-day readmissions (28.4% pre- vs. 24.6% post-intervention). Copyright© by the American Nephrology Nurses Association.

Entities:  

Keywords:  30-day readmissions; chronic kidney disease; end stage renal disease; post-discharge follow-up

Mesh:

Year:  2018        PMID: 30304617

Source DB:  PubMed          Journal:  Nephrol Nurs J        ISSN: 1526-744X            Impact factor:   0.959


  1 in total

1.  A Web-Based, Provider-Driven Mobile App to Enhance Patient Care Coordination Between Dialysis Facilities and Hospitals: Development and Pilot Implementation Study.

Authors:  Laura C Plantinga; Courtney Hoge; Ann E Vandenberg; Kyle James; Tahsin Masud; Anjali Khakharia; Carol Gray; Bernard G Jaar; Janice P Lea; Christopher M O'Donnell; Richard Mutell
Journal:  JMIR Form Res       Date:  2022-06-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.